• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Mike Tuffin Appointed President and CEO of AHIP

News
Article

Mike Tuffin is set to become AHIP's President and CEO from January 8, 2024, succeeding Julie Simon Miller.

Beginning January 8, 2024, Mike Tuffin, MBA, will take on the role of president and CEO of AHIP.

Tuffin is succeeding Matthew Eyles, who led the health insurance industry's trade group for five years before stepping down in September 2023. Julie Simon Miller, AHIP’s general counsel, served as the interim CEO.

Tuffin has been the senior vice president for external affairs for UnitedHealth Group since 2015. He is coming back to AHIP having served as executive vice president for public affairs of the organization from 2003 to 2012.

Tuffin's leadership will improve the organization’s mission of representing over 100 diverse companies providing healthcare coverage for millions of consumers and families, according to an AHIP news release about selection of Tuffin.

The chair of AHIP’s Board of Directors, David Holmberg, mentioned in the press release that the search for the position was thorough when trying to find a “forward-looking leader and advocate with extensive healthcare experience.”

“As a corporate executive, association leader and consultant, Mike has demonstrated an ability to successfully lead teams, partner with key stakeholders and advance policy outcomes that are critical to the health and security of the people our industry serves,” Holmberg said.

“Millions of American families and employers count on AHIP’s members for their coverage and care and for support in navigating our complex health care system,” Tuffin said in the press release. “I am honored to join Julie and the high-performing AHIP team in advancing this critical work.”

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.